Managers

Data Spotlight: Top 10 deals in March

Biotech firm Inozyme fetches $67 mln

Boston-based Inozyme Pharma Inc, a biotechnology company, has raised $67 million in Series A2 financing. Pivotal bioVenture Partners and Sofinnova Investments led the round.

Slow Ventures collects $220 mln for two funds

Slow Ventures has raised $220 million for two funds, according to a Medium blog post. The firm's fourth seed fund Slow IV has secured $165 million while its inaugural opportunity fund Slow Opportunity I raised $55 million. Based in San Francisco, the venture firm invests in the tech sector.

Cultivate(MD) backs HAPPE Spine

Grand Rapids, Michigan-based HAPPE Spine, a provider of PEEK interbody implants, has raised an undisclosed amount of funding. The investor was cultivate(MD).

Gene therapy platform AskBio snags $235 mln

North Carolina-based AskBio, a gene therapy platform, has secured $235 million in funding. The investors included TPG Capital and Vida Ventures.

Venture fundraising remains strong in Q1, $12.8 bln raised

Pearson launches $50 mln edtech corporate venture fund

Defy closes Fund II at oversubscribed $262 mln, about 75 pct larger than Fund I

Dick Kramlich's Green Bay Ventures raises $51.9 mln toward venture-capital fund

Dick Kramlich's Green Bay Ventures has raised $51.9 million toward a second venture-capital fund, according to a filing with the SEC.

Kairos Ventures is seeking $100 mln for first opportunities fund